Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma
NCT00499616Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Oct 2007
- Primary completion
- Jun 2014
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 6
01
Overview
A Phase 3 trial of carboplatin, cyclophosphamide, pegylated liposomal doxorubicin, etoposide in neuroblastoma, sponsored by Children's Oncology Group. Started Oct 2007; status: completed.
02
Drugs
carboplatincyclophosphamidepegylated liposomal doxorubicinetoposide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00499616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499616.